Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

NCT03012321 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT03012321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03012321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 12, 2017
Completion date
January 16, 2027
Enrollment
70 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

abnormal dna repair, metastatic prostate carcinoma, prostate cancer metastatic castration-resistant, stage iv prostate cancer